Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Cardlytics Inc’s stock clocked out at $2.17, up 12.14% from its previous closing price of $1.93. In other words, the price has increased by $12.14 from its previous closing price. On the day, 1.12 million shares were traded.
Ratios:
To gain a deeper understanding of CDLX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 111.69. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.19. In the meantime, Its Debt-to-Equity ratio is 3.44 whereas as Long-Term Debt/Eq ratio is at 2.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on October 11, 2024, initiated with a In-line rating and assigned the stock a target price of $4.
On August 16, 2024, Northland Capital Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $5.
BofA Securities Downgraded its Neutral to Underperform on August 15, 2024, whereas the target price for the stock was revised from $4 to $3.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 22 ’25 when Lynton Nicholas Hollmeyer sold 303 shares for $1.51 per share. The transaction valued at 458 led to the insider holds 102,119 shares of the business.
Lynton Nicholas Hollmeyer bought 303 shares of CDLX for $458 on Apr 22 ’25. On Apr 02 ’25, another insider, Gupta Amit, who serves as the Chief Executive Officer of the company, sold 7,342 shares for $1.81 each. As a result, the insider received 13,260 and left with 371,080 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 1.77.
Stock Price History:
Over the past 52 weeks, CDLX has reached a high of $10.01, while it has fallen to a 52-week low of $1.22. The 50-Day Moving Average of the stock is 16.09%, while the 200-Day Moving Average is calculated to be -35.83%.
Shares Statistics:
A total of 52.17M shares are outstanding, with a floating share count of 49.87M. Insiders hold about 5.01% of the company’s shares, while institutions hold 57.29% stake in the company.
Earnings Estimates
The current rating of Cardlytics Inc (CDLX) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.01 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.26 and -$0.65 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.53, with 2.0 analysts recommending between -$0.53 and -$0.53.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $64.06M. It ranges from a high estimate of $64.77M to a low estimate of $63.31M. As of the current estimate, Cardlytics Inc’s year-ago sales were $69.64MFor the next quarter, 5 analysts are estimating revenue of $68.21M. There is a high estimate of $70.3M for the next quarter, whereas the lowest estimate is $66.28M.
A total of 6 analysts have provided revenue estimates for CDLX’s current fiscal year. The highest revenue estimate was $275.75M, while the lowest revenue estimate was $259.8M, resulting in an average revenue estimate of $270.55M. In the same quarter a year ago, actual revenue was $278.3MBased on 5 analysts’ estimates, the company’s revenue will be $287.04M in the next fiscal year. The high estimate is $306.09M and the low estimate is $269.9M.
